15 results about "Pollen Allergy" patented technology

The invention provides a humic acid type plant pollen sensitization inhibitor as well as a preparation method and a use method thereof, and the humic acid type plant pollen sensitization inhibitor is prepared from the following raw materials in parts by mass: 1 to 2 parts of polyvinyl alcohol, 0.01 to 0.05 part of guar gum, 2 to 10 parts of acrylic acid, 0.05 to 0.2 part of initiator, 0.5 to 2 parts of potassium humate and 50 to 250 parts of water. The humic acid type plant pollen allergy inhibitor is environment-friendly and low in cost, and has good biocompatibility and allergy inhibition effect.

Tree pollen allergy is seasonal allergy caused by various tree pollen spread in air. The allergy affects a substantial proportion of populations, is particularly significant in European and North America areas, and is characterized by symptoms such as sneezing, nasal obstruction, rhinorrhea, eye itching and lacrimation, and throat irritation. The symptoms typically occur in spring, at which birch, alder, hazel and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by an immunoglobulin E (IgE) antibody. The present invention relates to antibodies and antigen binding fragments thereof that bind to one or more of tree pollen allergens Bet v 1, Aln g 1, Cor a 1 and Quue a 1, resulting in inhibition of IgE-mediated anaphylaxis.

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also 5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and / or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

Tree pollen allergy is a seasonal allergy caused by various tree pollens suspended in the air. This allergy affects a significant proportion of the population, particularly in Europe and North America, and is characterized by symptoms such as sneezing, nasal congestion, runny nose, itchy or watery eyes, and throat inflammation. These symptoms typically occur in spring when trees such as birch, alder, hazel, and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by immunoglobulin E (IgE) antibodies. This invention relates to antibodies and their antigen-binding fragments that bind to one or more tree pollen allergens, Bet v 1, Aln g 1, Cor a 1, and Que a 1, and inhibit the IgE-mediated allergic reaction.

This invention relates to the field of biopharmaceutical technology, and more particularly to a type of beeswax ( Fraxinus pennsylvanica This invention relates to a pollen allergen composition, its preparation method, and its application. It reveals that Chinese ash pollen contains more different allergenic proteins compared to European and American ash pollen. Therefore, using Chinese ash pollen as raw material, the resulting ash pollen allergen composition contains novel allergenic protein components that bind more strongly to the serum of Chinese ash pollen allergy patients, resulting in superior efficacy. This invention utilizes the ash pollen allergen composition to prepare a kit. This kit is highly sensitive, highly specific, and easy to operate. By changing the enzyme conjugate, it can be used for two purposes in one kit, achieving dual functions: detection of ash pollen allergen-specific IgE antibodies (in vitro allergen diagnosis) and quantitative detection of IgG antibodies (evaluation of desensitization therapy efficacy) in allergy patients.

The invention discloses an mRNA pollen allergy vaccine and application, and belongs to the technical field of biological medicine. A coding gene segment of the pollen allergen mRNA disclosed by the invention comprises nucleotides as shown in SEQ ID NO.1-4; the pollen allergen mRNA contains at least one of 5 'UTR, 3' UTR and PolyA, the mRNA pollen allergy vaccine is obtained after the pollen allergen mRNA is loaded by the vaccine vector, and the obtained mRNA pollen allergy vaccine can effectively promote generation of antigen-specific regulatory T cells (Treg) and Th1-sex immune response, so that the treatment of pollen allergy is realized. A new thought is provided for the development of pollen allergy treatment and prevention vaccines.

The present application provides a kind of shrub directional replacement of Ordos region Artemisia ordosica ecological planting method, belongs to the technical field of ecological restoration in desertification area, as follows: S1, shrub screening and seedling raising: screening local dominant shrub of Ordos, using degradable nutrient bag to raise seedling, obtain bagged seedling;S2, inhibitor application: in target area, Artemisia ordosica inhibitor is sprayed to Artemisia ordosica, to inhibit the growth of Artemisia ordosica;S3, shrub directional planting: in the target area after inhibitor treatment, the bagged seedling is planted;S4, community structure optimization: in the gap between shrubs after planting, local gramineous grass seeds are sown, and mixed plant community structure is constructed;After the method of the present application, the height, coverage and density of Artemisia ordosica are significantly reduced, there is no rebound fluctuation, the stability and persistence of the inhibition effect are significantly improved, and the reduction of Artemisia ordosica population effectively reduces the regional pollen release amount, which relieves the problem of pollen allergy from the source.

The invention provides a pollen vaccine based on an aluminum-CpG composite adjuvant and application of the pollen vaccine. The pollen vaccine comprises an aluminum-CpG chemical coupling nano adjuvant and a recombinant mugwort main allergen, the adjuvant is a substance formed by coupling an aluminum oxygen hydride nanorod and CpG through an amido bond, carboxyl on the surface of an AlOOH nanorod is activated, and then the AlOOH nanorod reacts with aminated CpG ODN to obtain the adjuvant. Stable combination of the aluminum salt nanoparticles and CpG ODN is achieved through chemical coupling, the coupling efficiency is larger than or equal to 95%, cytotoxicity is avoided, the problems that in traditional physical mixing, the aluminum salt nanoparticles and CpG ODN are not synergistic in effect and prone to dissociation are solved, and the synergistic immunoregulation effect of adjuvant components is ensured; after the adjuvant is loaded with the Artemisia pollen allergen Art v1, the IgE level can be remarkably reduced, lung inflammation can be relieved, allergic symptoms can be improved in treatment and prevention models, and a novel adjuvant platform is provided for immunotherapy of pollen allergy.

The invention discloses a method for constructing a Yunnan pine pollen allergy animal model, which belongs to the technical field of Yunnan pine pollen allergy prevention and treatment and comprises the following steps: preparing Yunnan pine pollen allergens and sensitizing non-human mammals. The sensitization treatment comprises a basic sensitization treatment stage and an excitation sensitization treatment stage: in the basic sensitization treatment stage, peritoneal sensitization is carried out once a week and is continued for four weeks; in the nasal-drop sensitization treatment stage, different test substances with the concentration 2 times that of the basic sensitization stage are used for continuous 7-day quantitative nasal-drop excitation, and the nasal drop dosage is 2 microliters / g, and the symptoms of the mouse are observed within 10 minutes after nasal-drop excitation is completed each time. The allergic animal model constructed by adopting the crude extract of the pinus yunnanensis pollen allergen is the first animal model research related to pinus yunnanensis allergy at present, and a reference basis can be provided for subsequent experimental research on the aspect of deep research on pinus yunnanensis pollen allergy; a research model is provided for clinical research on the Yunnan pine pollen allergy or screening of medicines for resisting the Yunnan pine pollen allergy.

The application discloses a kind of Sabina pollen aerosol chemical component detection and feature database construction method, comprising the following steps: (1) sample processing: collecting Sabina flower, after drying and crushing, extraction is obtained to be measured solution;(2) using the method of ultra-high performance liquid chromatography-quadrupole / or electrostatic field orbitrap high-resolution mass spectrometry, small molecule chemical components in Sabina pollen are systematically separated and identified;(3) data processing: including database establishment, data acquisition and processing, relevant literature search, representative compound selection and cleavage rule derivation.The present application not only lays a theoretical foundation for the rapid screening of Sabina pollen allergenic small molecule markers, the analysis of allergenic mechanisms, and the prevention and control of spring pollen allergy, but also provides a referenceable technical method for the identification of chemical components and mass spectrometry behavior research of similar pollen plants.

The present invention provides antibodies that bind to a birch pollen allergen, in particular a Bet v 1 allergen, and also bind to a Bet v 1 homologous allergen. The invention also provides compositions and kits comprising different antibodies that bind to different, non-overlapping epitopes of Bet v 1 and Bet v 1 homologous proteins. Furthermore, the invention relates to the use of such antibodies, compositions and kits, for example for the prevention or treatment of tree pollen allergy and food-related allergy.

The invention provides an ecological planting method for directionally replacing Artemisia ordosica with Ordos region shrubs, and belongs to the technical field of ecological restoration in desertification regions, and the method specifically comprises the following steps: S1, shrub screening and seedling raising: screening Ordos local dominant shrubs, and adopting degradable nutrition bags for seedling raising to obtain bagged seedlings; s2, inhibitor application: spraying an Artemisia ordosica L. inhibitor on the Artemisia ordosica L. in the target area so as to inhibit the growth of the Artemisia ordosica L.; s3, shrub directional planting: planting the bagged seedlings in the target area treated by the inhibitor; s4, community structure optimization: in the shrub gaps after field planting, local gramineous grass seeds are sown, and a mixed plant community structure is constructed; after the method is used, the height, the coverage degree and the density of the artemisia ordosica are obviously reduced, rebound fluctuation is avoided, the stability and the persistence of the inhibition effect are remarkable, the regional pollen release amount is effectively reduced through subduction of the artemisia ordosica population, and the livelihood problem of pollen allergy is relieved from the source.

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and / or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

The invention provides a chewable tablet for enhancing immunity and a preparation method thereof. The chewable tablet can enhance immunity and prevent pollen allergy. The core of the method is that a chitosan-coated IL-4-siRNA and IL-13-siRNA compound is scientifically compatible with a sophora flower bud extract, and intervention is carried out from an early link of immunoregulation. The siRNA compound is used for specifically silencing gene expression of key cell factors IL-4 and IL-13 for driving anaphylaxis through an RNA interference technology, and an anaphylaxis signal is blocked from the source; the sophora flower bud extract is rich in flavonoid compounds, assists in inhibiting inflammatory reaction, and has synergistic interaction with siRNA to block anaphylactic reaction and enhance immunity.